Effect of Piperacillin-Tazobactam vs Meropenem on 30-Day Mortality for Patients With <i>E coli</i> or <i>Klebsiella pneumoniae</i> Bloodstream Infection and Ceftriaxone ResistancePatrick N. A. Harris, David L. Paterson, Matteo Bassetti et al.|JAMA|2018Cited by 761
The emerging threat of multidrug-resistant Gram-negative bacteria in urologyHosam M. Zowawi, David L. Paterson, Patrick N. A. Harris et al.|Nature Reviews Urology|2015Cited by 367
COVID-19 and ischemic stroke: a systematic review and meta-summary of the literatureYing Kiat Tan, Benjamin Yong‐Qiang Tan, Claire Goh et al.|Journal of Thrombosis and Thrombolysis|2020Cited by 323
β-lactam and β-lactamase inhibitor combinations in the treatment of extended-spectrum β-lactamase producing Enterobacteriaceae: time for a reappraisal in the era of few antibiotic options?Patrick N. A. Harris, David L. Paterson, Paul Anantharajah Tambyah|The Lancet Infectious Diseases|2015Cited by 205
Association Between Minimum Inhibitory Concentration, Beta-lactamase Genes and Mortality for Patients Treated With Piperacillin/Tazobactam or Meropenem From the MERINO StudyAndrew Henderson, Bassam Alalwan, David L. Paterson et al.|Clinical Infectious Diseases|2020Cited by 155